Traders sold shares of Dexcom (NASDAQ:DXCM) on strength during trading hours on Monday. $27.38 million flowed into the stock on the tick-up and $31.87 million flowed out of the stock on the tick-down, for a money net flow of $4.49 million out of the stock. Of all companies tracked, Dexcom had the 26th highest net out-flow for the day. Dexcom traded up $0.37 for the day and closed at $74.53
DXCM has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Dexcom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Northland Securities restated a “sell” rating and issued a $40.00 price objective on shares of Dexcom in a research report on Tuesday, January 16th. Jefferies Group increased their target price on shares of Dexcom from $58.00 to $70.00 and gave the company a “buy” rating in a report on Friday, December 22nd. BMO Capital Markets increased their target price on shares of Dexcom to $74.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, Oppenheimer set a $67.00 target price on shares of Dexcom and gave the company a “buy” rating in a report on Monday, February 12th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $68.68.
The company has a debt-to-equity ratio of 0.78, a quick ratio of 5.04 and a current ratio of 5.36. The company has a market capitalization of $6,451.71, a price-to-earnings ratio of -128.50 and a beta of -0.02.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.07. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. The business had revenue of $221.00 million during the quarter, compared to analysts’ expectations of $217.82 million. analysts anticipate that Dexcom will post -0.56 EPS for the current year.
In other news, Chairman Terrance H. Gregg sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $55.91, for a total transaction of $559,100.00. Following the completion of the transaction, the chairman now directly owns 484,559 shares of the company’s stock, valued at approximately $27,091,693.69. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 2,581 shares of the firm’s stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $68.44, for a total transaction of $176,643.64. Following the transaction, the executive vice president now directly owns 94,429 shares of the company’s stock, valued at $6,462,720.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,854 shares of company stock valued at $2,141,081. Corporate insiders own 1.70% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Dexcom during the 4th quarter worth approximately $116,000. Thompson Davis & CO. Inc. purchased a new stake in Dexcom in the 4th quarter worth approximately $137,000. Zions Bancorporation grew its stake in Dexcom by 36,222.2% in the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after acquiring an additional 3,260 shares during the period. Marco Investment Management LLC purchased a new stake in Dexcom in the 4th quarter worth approximately $201,000. Finally, D.A. Davidson & CO. purchased a new stake in Dexcom in the 4th quarter worth approximately $208,000.
WARNING: “Traders Sell Shares of Dexcom (DXCM) on Strength (DXCM)” was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://theenterpriseleader.com/2018/04/02/traders-sell-shares-of-dexcom-dxcm-on-strength-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.